Ying‐Chou Chen

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

Maxime Dougados, Désirée van der Heijde, Ying‐Chou Chen et al. · Annals of the Rheumatic Diseases · 2016 · 399 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case–control study

Chung‐Yuan Hsu, Ming‐Shyan Lin, Yu‐Jih Su et al. · Lara D. Veeken · 2016 · 79 citations · Full text

Medicine, Immunology, Oncology +14

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

Paul Emery, Ricardo Blanco, José Maldonado Cocco et al. · RMD Open · 2017 · 53 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus

Chung‐Yuan Hsu, Yu‐Sheng Lin, Tien‐Tsai Cheng et al. · Lara D. Veeken · 2018 · 51 citations · Full text

Pharmacy, Health Sciences, Pharmacotherapy +13